JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on March 2, 2005; DOI: 10.1124/jpet.105.083758


0022-3565/05/3133-1058-1065$20.00
JPET 313:1058-1065, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.105.083758v1
313/3/1058    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Naisbitt, D. J.
Right arrow Articles by Park, B. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Naisbitt, D. J.
Right arrow Articles by Park, B. K.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*PHENINDIONE

TOXICOLOGY

Characterization of the T-Cell Response in a Patient with Phenindione Hypersensitivity

Dean J. Naisbitt, John Farrell, Peter J. Chamberlain, Josephine E. Hopkins, Neil G. Berry, Munir Pirmohamed, and B. Kevin Park

Departments of Pharmacology (D.J.N., J.F., P.J.C., J.E.H., M.P., B.K.P.) and Chemistry (N.G.B.), The University of Liverpool, Liverpool, England

The oral anticoagulant phenindione [2-phenyl-1H-indene-1,3(2H)-dione] is associated with hypersensitivity reactions in 1.5 to 3% of patients, the pathogenesis of which is unclear. We describe a patient who developed a severe hypersensitivity reaction that involved both the skin and lungs. A lymphocyte transformation test showed proliferation of T-cells from the hypersensitive patient, but not from four controls on exposure to phenindione in vitro. Drug-specific T-cell clones were generated and characterized in terms of their phenotype, functionality, and mechanism of antigen presentation. Forty-three human leukocyte antigen class II restricted CD4+ {alpha}{beta} T-cell clones were identified. T-cell activation resulted in the secretion of interferon-{gamma} and interleukin-5. Five of seven clones proliferated with phenindione alone, whereas two clones also proliferated with 2-phenylindene. Certain T-cell clones were also stimulated by R- and S-warfarin; computer modeling revealed that warfarin can adopt a phenindione-like structure. Phenindione was presented to T-cells via two pathways: first, bound directly to major histocompatibility complex and second, bound to a processed peptide. Our data show that CD4+ T-cells are involved in the pathophysiology of phenindione hypersensitivity. There may be cross-sensitivity with warfarin in some phenindione hypersensitive patients.


Received for publication January 14, 2005
Accepted February 23, 2005.

Address correspondence to: Dr. Dean J. Naisbitt, Department of Pharmacology and Therapeutics, Sherrington Building, Ashton Street, The University of Liverpool, P.O. Box 147, Liverpool, L69 3GE, England. E-mail:dnes{at}liv.ac.uk




This article has been cited by other articles:


Home page
BMJHome page
B Doshi and S Sarkar
Topical administration of chloramphenicol can induce acute hepatitis
BMJ, June 12, 2009; 338(jun12_1): b1699 - b1699.
[Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.